| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3810/HP.2011.02.381 |
| P698 | PubMed publication ID | 21441766 |
| P2093 | author name string | David R P Guay | |
| P2860 | cites work | Structure-based design of novel potent nonpeptide thrombin inhibitors | Q27638874 |
| Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement | Q28245267 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
| Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) | Q28284893 | ||
| Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) | Q28284905 | ||
| The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q33346026 | ||
| Argatroban: a review of its use in the management of heparin-induced thrombocytopenia | Q33385668 | ||
| Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects | Q33438731 | ||
| The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty | Q46395414 | ||
| Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q46522906 | ||
| Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q46522912 | ||
| Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q46522917 | ||
| Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q46522922 | ||
| The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans | Q46897672 | ||
| Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). | Q46939643 | ||
| Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement | Q50281577 | ||
| Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. | Q51921624 | ||
| Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. | Q55044458 | ||
| Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. | Q55044630 | ||
| Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery | Q34012097 | ||
| A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey | Q34105149 | ||
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | Q34134664 | ||
| Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate | Q34590281 | ||
| Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788523 | ||
| Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788530 | ||
| Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788539 | ||
| Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development | Q34900298 | ||
| New anticoagulants for atrial fibrillation | Q35001733 | ||
| Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation | Q35003773 | ||
| Dabigatran versus warfarin in the treatment of acute venous thromboembolism | Q35016336 | ||
| Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis | Q35827856 | ||
| Brave new world: the current and future use of novel anticoagulants | Q37286448 | ||
| Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors | Q37534122 | ||
| Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). | Q37568357 | ||
| Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal | Q37608696 | ||
| The new oral anticoagulants | Q37625561 | ||
| Using low molecular weight heparin in special patient populations | Q37630371 | ||
| Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications | Q37692386 | ||
| The use and limitations of unfractionated heparin | Q37705774 | ||
| Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? | Q37721619 | ||
| Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials | Q37733438 | ||
| Role of warfarin pharmacogenetic testing in clinical practice | Q37733582 | ||
| Bivalirudin: in patients with ST-segment elevation myocardial infarction | Q37738870 | ||
| The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q38899222 | ||
| A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. | Q40456744 | ||
| The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects | Q41121441 | ||
| Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. | Q42634446 | ||
| Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation | Q42839725 | ||
| Quality of anticoagulation control in atrial fibrillation | Q42923266 | ||
| Dabigatran may not be an effective anticoagulant for haemodialysis | Q42962506 | ||
| Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study | Q43137255 | ||
| Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor | Q43188577 | ||
| A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting | Q43267101 | ||
| Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q44210402 | ||
| Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. | Q45981193 | ||
| Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery | Q46108983 | ||
| Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics | Q46141539 | ||
| Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment | Q46338578 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vitamin | Q34956 |
| vitamin K | Q182338 | ||
| (E)-phytonadione | Q186093 | ||
| dabigatran | Q419345 | ||
| P304 | page(s) | 105-125 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Hospital Practice | Q5908551 |
| P1476 | title | Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists? | |
| P478 | volume | 39 |
Search more.